The city of New Orleans, Louisiana, currently has 9 active clinical trials seeking participants for COVID19 research studies.
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Recruiting
Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific cli... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Tulane Medical Center, New Orleans, Louisiana
Conditions: Infectious Pneumonia, Severe COVID-19
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
All
Ages:
Between 0 years and 20 years
Trial Updated:
03/29/2024
Locations: Tulane University Health Science Center, New Orleans, Louisiana +1 locations
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Recruiting
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/25/2024
Locations: Tulane Medical Center, New Orleans, Louisiana
Conditions: Community-acquired Pneumonia, Influenza, COVID-19
Intervention to Prevent Behavioral Health Symptoms Among Pandemic Affected Children
Recruiting
Racial and ethnic minority children who live in socioeconomically disadvantaged communities are disproportionately impacted by pandemic and climate-induced disasters. Although effective interventions have been designed to treat mental health related symptoms in post-disaster settings, accessible, empirically supported prevention interventions are needed to prevent the onset of mental and behavioral health issues among these children. Building on our preliminary findings, the proposed study exami... Read More
Gender:
All
Ages:
Between 8 years and 14 years
Trial Updated:
01/08/2024
Locations: Coalition for Compassionate Schools, New Orleans, Louisiana +1 locations
Conditions: Emotional Distress, Prosocial Behavior, Pandemic, COVID-19, Coping Skills, Social Support
Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development
Recruiting
Collection of SARS-COV-2 Secretions and Serum for Countermeasure Development (aka ClinSeqSer) is an observational study to understand natural history of SARS-COV-2 infections among special populations and characterise post-covid morbidity through immune response, virus genome sequencing, cytokine response, and virus shedding. Given the descriptions of infection course of patients over the outbreak of 2003 (SARS-Cov01) and since January 2019 in China and Europe, and now worldwide: Acutely infect... Read More
Gender:
All
Ages:
Between 6 months and 120 years
Trial Updated:
12/20/2023
Locations: Tulane University Medical Center, New Orleans, Louisiana +1 locations
Conditions: Covid19
Lupus Education Alliance Program
Recruiting
The purpose of this study is to evaluate the evaluate the effect of education-only vs. navigation interventions on COVID-19 testing and vaccination for people with systemic lupus erythematosus.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Tulane University, New Orleans, Louisiana
Conditions: Systemic Lupus Erythematosus, COVID-19
Effects of Immulina TM Supplements With PASC Patients
Recruiting
This is a multi-site study that will try to determine the effects of Immulina ™, a natural dietary supplement, on blood chemicals associated with inflammation that are often increased in patients with long COVID (also called PASC).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
08/29/2023
Locations: Louisiana State University, New Orleans, Louisiana +1 locations
Conditions: Post Acute COVID-19 Syndrome
ARrest RESpiraTory Failure From PNEUMONIA
Recruiting
This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/26/2023
Locations: Tulane University - Main & BUMC, New Orleans, Louisiana
Conditions: Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
Outpatient Liquid Aspirin (OLA)
Recruiting
The purpose of this study is to obtain reliable and interpretable data to inform future trials regarding our hypothesis that a novel, liquid aspirin formulation can mitigate COVID -19 associated coagulopathy (CAC) . The potential impact is to reduce COVID-19 related hospitalization within 30 days of diagnosis due to (1) pulmonary events including respiratory failure; (2) cardiac events including myocardial infarction and myocarditis (3) venous or arterial thrombotic events; (4) acute renal insuf... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
12/13/2021
Locations: Lsuhsc-No, New Orleans, Louisiana
Conditions: Covid19